Jay Hoofnagle

September 1993
U.S. News & World Report;9/13/93, Vol. 115 Issue 10, p21
Focuses on Jay Hoofnagle, a liver specialist at the National Institutes of Health who thought he had found a promising drug for hepatitis B treatment--fialuridine, or FIAU. Early drug tests; Recent death of fifth volunteer treated with FIAU.


Related Articles

  • The cure that killed. Thompson, Larry // Discover;Mar1994, Vol. 15 Issue 3, p56 

    Probes on the study on fialuridine (FIAU) conducted by director Jay Hoofnagle at the National Institutes of Health, for the treatment of hepatitis B, which in the process killed the patients involved. Background information on FIAU; Statistical information on hepatitis B; Side effects; Summary...

  • Viral Hepatitis and Liver Disease. Pertsemlidis, D.; Achord, James L. // American Journal of Gastroenterology;Mar1986, Vol. 81 Issue 3, p224 

    Reviews the book "Viral Hepatitis and Liver Disease," edited by G. N. Vyas, J. L. Dienstag and J. H. Hoofnagle.

  • 'Denialism' and muddying the waters. Stoff, Rick // St. Louis Journalism Review;Jun2007, Vol. 37 Issue 296, p21 

    The article focuses on "denialism." According to attorney Chris Jay Hoofnagle, it is easier to use denialist tactics than to face political and social problems head on. Agreeing to open a dialogue about such issues, he says, creates the risk of bringing to light problems that need regulatory or...

  • Peginterferon and Ribavirin for Hepatitis C. Hoofnagle, Jay H.; Seeff, Leonard B. // New England Journal of Medicine;3/22/2007, Vol. 356 Issue 12, p1271 

    A reply by Jay H. Hoofnagle and Leonard B. Seeff to letters to the editor about their article "Peginterferon and ribavirin for chronic hepatitis C," published in the December 7, 2006 issue is presented.

  • Randomized, Controlled Trial of Recombinant Human α-Interferon in Patients With Chronic Hepatitis B.  // JAMA: Journal of the American Medical Association;6/16/89, Vol. 261 Issue 23, p3399 

    Discusses the abstract of the article 'Randomized, Controlled Trial of Recombinant Human Alpha-Interferon in Patients With Chronic Hepatitis B,' by Jay H. Hoofnagle et al., published in a 1988 issue of the 'Gastroenterology' journal.

  • Reply to Antonucci et al. Hoofnagle, Jay H.; Wahed, Abdus S.; Belle, Steven H. // Journal of Infectious Diseases;11/1/2009, Vol. 200 Issue 9, p1485 

    A response by Jay H. Hoofnagle, Abdus S. Wahed and Steven H. Belle to a letter to the editor about their article on the role of younger age in sustained virological response (SVR) to combination therapy for chronic hepatitis C.

  • Hepatitis gene is shown to cause liver cancer.  // New Scientist;5/25/91, Vol. 130 Issue 1770, p23 

    Reveals that a team of scientists from the US and Japan have discovered the link between liver cancer and hepatitis B. Collaboration between Gilbert Jay at the Jerome H. Holland Laboratory of the American Red Cross and colleagues in Japan's National Institute of Health; Involvement of the HBx...

  • Alcohol and the Liver. ROSE, VERNA L. // American Family Physician;2/1/1999, Vol. 59 Issue 3, p700 

    Focuses on the report `Alcohol and the Liver: Research Update,' from the National Institute on Alcohol Abuse and Alcoholism. Medical consequences of alcoholism; Factors that increase the risk for advanced liver damage; Suggested treatment.

  • Service provision for liver disease in the UK: a national questionnaire-based survey. Scott, R; Williams, M; Lawson, A; Austin, A; Freeman, J // Clinical Medicine;Apr2012, Vol. 12 Issue 2, p114 

    The article presents the results of a national questionnaire survey of liver services, which focused on staffing and training, access to key facilities and clinical management of liver disease in the UK. The survey was conducted because the National Plan for Liver Services in 2009 called for a...


Read the Article

Other Topics